When baseline values differed between groups, analysis of covariance was used to adjust and make between-group

comparisons. Paired t-tests were used for within-group comparisons. Nonnormally distributed outcome variables (area under the curve for glucose and insulin) were log-transformed before making any comparisons. Integrated insulin and glucose areas under the curve were measured Dabrafenib supplier using the trapezoidal method. All other outcomes were normally distributed. Spearman rank correlation coefficients were used to evaluate associations between variables. P<0.05 (two-tailed) was considered significant. Fifty participants completed the intervention, and at baseline the two groups were matched for age, gender, race, years known to be HIV infected, immune and Selleckchem Pirfenidone virological status,

current use of cART, past medical history of CVD, diabetes, hypertension, and alcohol and tobacco use (Table 1). None of the participants changed cART during the study. At baseline, 38% of participants were using tobacco, 26% had a history of hypertension, 42% had pre-hypertension (120–139/80–89 mmHg; AHA criteria [40]) and 24% had impaired glucose tolerance (American Diabetes Association (ADA) criteria [41]), and although the average per cent body fat was normal (23–24%), the average waist circumference was high (men, 97 ± 21 cm; women, 100 ± 14 cm), suggesting that most of the body fat was located centrally. The baseline Framingham CVD risk score was similar between the groups, and indicated mild–moderate 10-year CVD risk. However, 14% of the participants in each group had baseline Framingham CVD risk scores that were

>10% (moderate–high risk). On average, yoga participants attended 33 ± 7 sessions; the minimum number of sessions attended was 14 and the maximum was 45 during the 20-week yoga programme. After 20 weeks, CD4 T-cell count and HIV RNA levels were unchanged in the yoga (495 ± 155 to 507 ± 134 cells/μL; 90–83% undetectable) and standard of care groups (570 ± 256 to 592 ± 268 cells/μL; 90–90% undetectable). Average baseline glucose and insulin levels and homeostasis model assessment (HOMA) (Table 1) were normal and not different between groups. Oral glucose tolerance and insulin action were not improved after the yoga intervention Silibinin (Fig. 2). HOMA index, glucose and insulin levels and area under the curve during the oGTT were not different between the groups and did not change in either group after the interventions. Insulin levels and area under the curve during the oGTT tended to be lower after yoga (12%), but differences compared with the standard of care group were not statistically significant (P=0.46). Baseline serum triglycerides and total and non-HDL cholesterol levels were higher in the yoga group than in the standard of care group (Fig. 3; P<0.04).